Mirodenafil (dihydrochloride) structure
|
Common Name | Mirodenafil (dihydrochloride) | ||
---|---|---|---|---|
CAS Number | 862189-96-6 | Molecular Weight | 604.58900 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H39Cl2N5O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Mirodenafil (dihydrochloride)Mirodenafil 2Hcl(SK3530 2Hcl) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.Target: PDE5Mirodenafil is a newly developed oral phosphodiesterase type 5 inhibitor. Mirodenafil, in doses of 50 or 100 mg, significantly improved erectile function and were well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities [1]. The concurrent administration of mirodenafil with alcohol was not associated with clinically significant hemodynamic changes in these healthy male volunteers in Korea. The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil administered with alcohol had a tolerability profile comparable to that of mirodenafil alone [2]. In these healthy Korean male volunteers, the coadministration of ketoconazole and rifampicin resulted in significant changes in systemic exposure to mirodenafil [3]. |
Name | 5-Ethyl-2-(5-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}-2-propo xyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one d ihydrochloride |
---|---|
Synonym | More Synonyms |
Description | Mirodenafil 2Hcl(SK3530 2Hcl) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.Target: PDE5Mirodenafil is a newly developed oral phosphodiesterase type 5 inhibitor. Mirodenafil, in doses of 50 or 100 mg, significantly improved erectile function and were well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities [1]. The concurrent administration of mirodenafil with alcohol was not associated with clinically significant hemodynamic changes in these healthy male volunteers in Korea. The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil administered with alcohol had a tolerability profile comparable to that of mirodenafil alone [2]. In these healthy Korean male volunteers, the coadministration of ketoconazole and rifampicin resulted in significant changes in systemic exposure to mirodenafil [3]. |
---|---|
Related Catalog | |
References |
Molecular Formula | C26H39Cl2N5O5S |
---|---|
Molecular Weight | 604.58900 |
Exact Mass | 603.20500 |
PSA | 129.40000 |
LogP | 5.42430 |
Storage condition | 2-8℃ |
Mirodenafil (dihydrochloride) |